These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31350321)

  • 81. Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.
    Weiss J; Martirosian P; Notohamiprodjo M; Kaufmann S; Othman AE; Grosse U; Nikolaou K; Gatidis S
    Invest Radiol; 2018 Mar; 53(3):186-190. PubMed ID: 29077588
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.
    Simmons LAM; Kanthabalan A; Arya M; Briggs T; Barratt D; Charman SC; Freeman A; Gelister J; Hawkes D; Hu Y; Jameson C; McCartan N; Moore CM; Punwani S; Ramachandran N; van der Meulen J; Emberton M; Ahmed HU
    Br J Cancer; 2017 Apr; 116(9):1159-1165. PubMed ID: 28350785
    [TBL] [Abstract][Full Text] [Related]  

  • 83. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
    Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
    BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
    Mannaerts CK; Kajtazovic A; Lodeizen OAP; Gayet M; Engelbrecht MRW; Jager GJ; Wijkstra H; de Reijke TM; Beerlage HP
    Urol Oncol; 2019 May; 37(5):298.e1-298.e9. PubMed ID: 30660493
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score.
    Jambor I; Falagario U; Ratnani P; Perez IM; Demir K; Merisaari H; Sobotka S; Haines GK; Martini A; Beksac AT; Lewis S; Pahikkala T; Wiklund P; Nair S; Tewari A
    J Magn Reson Imaging; 2020 Apr; 51(4):1075-1085. PubMed ID: 31566845
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The primacy of multiparametric MRI in men with suspected prostate cancer.
    Richenberg J; Løgager V; Panebianco V; Rouviere O; Villeirs G; Schoots IG
    Eur Radiol; 2019 Dec; 29(12):6940-6952. PubMed ID: 31172275
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
    AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
    Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
    BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 18F-Choline PET/MR Can Detect and Delineate Local Recurrence After High-Intensity Focused Ultrasound Therapy of Prostate Cancer.
    Burger IA; Gafita A; Müller J; Kranzbühler B; Donati OF; Eberli D
    Clin Nucl Med; 2018 Apr; 43(4):e111-e112. PubMed ID: 29432339
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results.
    Hansen N; Patruno G; Wadhwa K; Gaziev G; Miano R; Barrett T; Gnanapragasam V; Doble A; Warren A; Bratt O; Kastner C
    Eur Urol; 2016 Aug; 70(2):332-40. PubMed ID: 26995327
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pelvic phased-array mpMRI versus saturation biopsy: a diagnostic performance analysis in men with suspected advanced prostate cancer.
    Liu G; Yan T
    Scand J Urol; 2020 Feb; 54(1):14-19. PubMed ID: 32026731
    [No Abstract]   [Full Text] [Related]  

  • 93. Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging.
    Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
    Biomed Res Int; 2020; 2020():2819701. PubMed ID: 32337234
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.
    Paparo F; Piccardo A; Bacigalupo L; Romagnoli A; Piccazzo R; Monticone M; Cevasco L; Campodonico F; Conzi GM; Carmignani G; Rollandi GA
    Abdom Imaging; 2015 Aug; 40(6):1772-87. PubMed ID: 25579170
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores.
    Barkovich EJ; Shankar PR; Westphalen AC
    AJR Am J Roentgenol; 2019 Apr; 212(4):847-854. PubMed ID: 30807218
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Accuracy of multiparametric magnetic resonance imaging to detect significant prostate cancer and index lesion location.
    Goldman H; Singh N; Harding C; McGirr J; Seal A; Duncan I; Sowter S
    ANZ J Surg; 2019 Jan; 89(1-2):106-110. PubMed ID: 30257273
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
    Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
    J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
    [TBL] [Abstract][Full Text] [Related]  

  • 98. False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Stavrinides V; Syer T; Hu Y; Giganti F; Freeman A; Karapanagiotis S; Bott SRJ; Brown LC; Burns-Cox N; Dudderidge TJ; Bosaily AE; Frangou E; Ghei M; Henderson A; Hindley RG; Kaplan RS; Oldroyd R; Parker C; Persad R; Rosario DJ; Shergill IS; Echeverria LMC; Norris JM; Winkler M; Barratt D; Kirkham A; Punwani S; Whitaker HC; Ahmed HU; Emberton M;
    Eur Urol; 2021 Jan; 79(1):20-29. PubMed ID: 33051065
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
    BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Advancement of MR and PET/MR in Prostate Cancer.
    Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
    Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.